Moleculin Biotech

MBRXNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$11.005 M

$0.57 +8.61%

Close of 22 Sept 2026

Revenue

$0.00

#3637 by revenue

Earnings

$33.6M

#1712 by earnings

Shares outstanding

19,477,380

Latest filing cover page

P/E ratio

0.3

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#429MetaViaMTVA$11.1M
#430Adial PharmaceuticalsADIL$11.0M
#431Moleculin BiotechMBRX$11.0M
#432CytoMed TherapeuticsGDTC$10.8M
#433Theriva BiologicsTOVX$10.6M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of Moleculin Biotech, worth $0.00. Grants and option exercises are excluded.

Donald H. PickerChief Science Officer$0.00
173,333 shares on 3 Aug 2026 · filed 5 Aug 2026
Walter Klemp VCEO and President$0.00
533,333 shares on 3 Aug 2026 · filed 5 Aug 2026
Jonathan P. FosterChief Financial Officer$0.00
293,333 shares on 3 Aug 2026 · filed 5 Aug 2026

What if Moleculin Biotech were worth as much as…

Open the what-if tool →

Gold $30.2T

$1,552,261

Per share 2,747,364× higher

Bitcoin $1.74T

$89,419.37

Per share 158,264× higher

Nvidia $5.52T

$283,188.34

Per share 501,218× higher

Or at a round number

$20.0M $50.0M $100.0M $200.0M

Where these numbers come from

Share counts and financials for Moleculin Biotech are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.